Selected research
Industry Research
Capecitabine Fumarate Industry Research Report 2026
Market perspective
The global Capecitabine Fumarate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Capecitabine Fumarate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Capecitabine Fumarate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Capecitabine Fumarate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Capecitabine Fumarate include Akorn, Dr Reddys, Emcure Pharms, Gland Pharma, Hikma Farmaceutica, Sagent Pharms, Sun Pharma Global, Pfizer and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Capecitabine Fumarate market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Capecitabine Fumarate Market by Company
Akorn
Dr Reddys
Emcure Pharms
Gland Pharma
Hikma Farmaceutica
Sagent Pharms
Sun Pharma Global
Pfizer
Mylan
Novartis
Capecitabine Fumarate Segment by Type
Capecitabine Fumarate Oral
Capecitabine Fumarate Infusion
Capecitabine Fumarate Segment by Application
Colon Cancer
Breast Cancer
Gastric Cancer
Rectal Cancer
Other Malignancies
Capecitabine Fumarate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Capecitabine Fumarate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Capecitabine Fumarate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Capecitabine Fumarate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Capecitabine Fumarate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Capecitabine Fumarate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Capecitabine Fumarate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capecitabine Fumarate Oral
- Capecitabine Fumarate Infusion
Applications
- Colon Cancer
- Breast Cancer
- Gastric Cancer
- Rectal Cancer
- Other Malignancies
Companies covered
- Akorn
- Dr Reddys
- Emcure Pharms
- Gland Pharma
- Hikma Farmaceutica
- Sagent Pharms
- Sun Pharma Global
- Pfizer
- Mylan
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Capecitabine Fumarate Market Size (2021-2032)
- 2.2.2 Global Capecitabine Fumarate Sales (2021-2032)
- 2.2.3 Global Capecitabine Fumarate Market Average Price (2021-2032)
- 2.3 Capecitabine Fumarate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capecitabine Fumarate Oral
- 2.3.3 Capecitabine Fumarate Infusion
- 2.4 Capecitabine Fumarate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Colon Cancer
- 2.4.3 Breast Cancer
- 2.4.4 Gastric Cancer
- 2.4.5 Rectal Cancer
- 2.4.6 Other Malignancies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Capecitabine Fumarate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Capecitabine Fumarate Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Capecitabine Fumarate Revenue of Manufacturers (2021-2026)
- 3.4 Global Capecitabine Fumarate Average Price by Manufacturers (2021-2026)
- 3.5 Global Capecitabine Fumarate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Capecitabine Fumarate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Capecitabine Fumarate, Product Type & Application
- 3.8 Global Manufacturers of Capecitabine Fumarate, Established Date
- 3.9 Global Capecitabine Fumarate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Akorn
- 4.1.1 Akorn Company Information
- 4.1.2 Akorn Business Overview
- 4.1.3 Akorn Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Akorn Capecitabine Fumarate Product Portfolio
- 4.1.5 Akorn Recent Developments
- 4.2 Dr Reddys
- 4.2.1 Dr Reddys Company Information
- 4.2.2 Dr Reddys Business Overview
- 4.2.3 Dr Reddys Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Dr Reddys Capecitabine Fumarate Product Portfolio
- 4.2.5 Dr Reddys Recent Developments
- 4.3 Emcure Pharms
- 4.3.1 Emcure Pharms Company Information
- 4.3.2 Emcure Pharms Business Overview
- 4.3.3 Emcure Pharms Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Emcure Pharms Capecitabine Fumarate Product Portfolio
- 4.3.5 Emcure Pharms Recent Developments
- 4.4 Gland Pharma
- 4.4.1 Gland Pharma Company Information
- 4.4.2 Gland Pharma Business Overview
- 4.4.3 Gland Pharma Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gland Pharma Capecitabine Fumarate Product Portfolio
- 4.4.5 Gland Pharma Recent Developments
- 4.5 Hikma Farmaceutica
- 4.5.1 Hikma Farmaceutica Company Information
- 4.5.2 Hikma Farmaceutica Business Overview
- 4.5.3 Hikma Farmaceutica Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hikma Farmaceutica Capecitabine Fumarate Product Portfolio
- 4.5.5 Hikma Farmaceutica Recent Developments
- 4.6 Sagent Pharms
- 4.6.1 Sagent Pharms Company Information
- 4.6.2 Sagent Pharms Business Overview
- 4.6.3 Sagent Pharms Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sagent Pharms Capecitabine Fumarate Product Portfolio
- 4.6.5 Sagent Pharms Recent Developments
- 4.7 Sun Pharma Global
- 4.7.1 Sun Pharma Global Company Information
- 4.7.2 Sun Pharma Global Business Overview
- 4.7.3 Sun Pharma Global Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sun Pharma Global Capecitabine Fumarate Product Portfolio
- 4.7.5 Sun Pharma Global Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Capecitabine Fumarate Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Mylan
- 4.9.1 Mylan Company Information
- 4.9.2 Mylan Business Overview
- 4.9.3 Mylan Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mylan Capecitabine Fumarate Product Portfolio
- 4.9.5 Mylan Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Capecitabine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Capecitabine Fumarate Product Portfolio
- 4.10.5 Novartis Recent Developments
5 Global Capecitabine Fumarate Market Scenario by Region
- 5.1 Global Capecitabine Fumarate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Capecitabine Fumarate Sales by Region: 2021-2032
- 5.2.1 Global Capecitabine Fumarate Sales by Region: 2021-2026
- 5.2.2 Global Capecitabine Fumarate Sales by Region: 2027-2032
- 5.3 Global Capecitabine Fumarate Revenue by Region: 2021-2032
- 5.3.1 Global Capecitabine Fumarate Revenue by Region: 2021-2026
- 5.3.2 Global Capecitabine Fumarate Revenue by Region: 2027-2032
- 5.4 North America Capecitabine Fumarate Market Facts & Figures by Country
- 5.4.1 North America Capecitabine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Capecitabine Fumarate Sales by Country (2021-2032)
- 5.4.3 North America Capecitabine Fumarate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Capecitabine Fumarate Market Facts & Figures by Country
- 5.5.1 Europe Capecitabine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Capecitabine Fumarate Sales by Country (2021-2032)
- 5.5.3 Europe Capecitabine Fumarate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Capecitabine Fumarate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Capecitabine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Capecitabine Fumarate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Capecitabine Fumarate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Capecitabine Fumarate Market Facts & Figures by Country
- 5.7.1 South America Capecitabine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Capecitabine Fumarate Sales by Country (2021-2032)
- 5.7.3 South America Capecitabine Fumarate Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Capecitabine Fumarate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Capecitabine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Capecitabine Fumarate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Capecitabine Fumarate Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Capecitabine Fumarate Sales by Type (2021-2032)
- 6.1.1 Global Capecitabine Fumarate Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Capecitabine Fumarate Sales Market Share by Type (2021-2032)
- 6.2 Global Capecitabine Fumarate Revenue by Type (2021-2032)
- 6.2.1 Global Capecitabine Fumarate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Capecitabine Fumarate Revenue Market Share by Type (2021-2032)
- 6.3 Global Capecitabine Fumarate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Capecitabine Fumarate Sales by Application (2021-2032)
- 7.1.1 Global Capecitabine Fumarate Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Capecitabine Fumarate Sales Market Share by Application (2021-2032)
- 7.2 Global Capecitabine Fumarate Revenue by Application (2021-2032)
- 7.2.1 Global Capecitabine Fumarate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Capecitabine Fumarate Revenue Market Share by Application (2021-2032)
- 7.3 Global Capecitabine Fumarate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Capecitabine Fumarate Value Chain Analysis
- 8.1.1 Capecitabine Fumarate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Capecitabine Fumarate Production Mode & Process
- 8.2 Capecitabine Fumarate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Capecitabine Fumarate Distributors
- 8.2.3 Capecitabine Fumarate Customers
9 Global Capecitabine Fumarate Analyzing Market Dynamics
- 9.1 Capecitabine Fumarate Industry Trends
- 9.2 Capecitabine Fumarate Industry Drivers
- 9.3 Capecitabine Fumarate Industry Opportunities and Challenges
- 9.4 Capecitabine Fumarate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst